Clearside Biomedical Inc diskutieren
Clearside Biomedical Inc
WKN: A2ALP6 / Symbol: CLSD / Name: Clearside / Aktie / Micro Cap /
Clearside Biomedical: Upside Into Q4 Data And NDA Submission
Positive data in the pivotal PEACHTREE study adds an element of derisking and downside cushion.
Clinical and regulatory catalysts later this year are likely to spur a run up.
Für zukünftige Katalysatoren plant das Unternehmen die NDA für suprachoroidale CLS-TA bei Patienten mit Makulaödem im Zusammenhang mit Uveitis bei der FDA einzureichen.
SecteurRecherche biotechnologique et médicale Agenda 17/09 Présentation
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy.
The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Nombre d'employés : 34 personnes.
Könnte
was werden. Große Summe wurde investiert.
CLSD as the FDA accepted its marketing application
The FDA accepted its marketing application seeking approval for XIPERE (triamcinolone acetonide ophthalmic solution) for Suprachoroidal Injection (area in the posterior segment of the eye) for the treatment of macular edema associated with uveitis.
The agency's action date is October 19 (under the 505(b)(2) pathway).
Der Beitrag wurde gelöscht
Neueste Beiträge
WatchMen in Soleno Therapeutics Inc. diskutieren